IDX e-IPO Analytics

Thesis

PT Nitrasanata Dharma Tbk (JECX) brings to market the operator of JEC – Jakarta Eye Center, Indonesia's most established eye-care specialist: five specialty eye hospitals and 11 eye clinics across Jadetabek, Central Java, East Java, Bali, and Sulawesi, with a brand dating to 1984 and JCI accreditation (four consecutive periods) at one hospital. The core franchise is a genuine asset. But this is structured as a deleveraging and liquidity-event IPO, not a growth-capital raise. The defining feature is that public money substantially backfills a pre-IPO extraction: at every price in the Rp1,200–1,400 range, the majority of what the company itself raises repays bank debt, and the single largest debt line — Rp100bn to HSBC — repays a dividend-recap loan signed roughly 10 weeks before listing. Layered on top are a near-total founder-doctor cash-out in the secondary tranche, a 2024 profit collapse only partially recovered, covenant breaches at two subsidiaries, and a valuation in the low-60s P/E. The opportunity is a strong brand resetting its cost of capital; the question is how much of the raise actually reaches the business.

How the business works

JEC operates an integrated eye-care network spanning the full continuum of care — from routine clinics through to tertiary specialty hospitals — letting it triage and escalate patients within its own system rather than referring them out. Revenue is multi-stream (self-pay, private insurance, and BPJS), which is precisely why the auditor named revenue recognition the Key Audit Matter for FY2025. Demand sits on a structural tailwind the company foregrounds: a 284.4m population that is aging and increasingly diabetic (20.4m diabetics in 2024, projected ~28.6m by 2050), which drives eye-care volume. The economics split cleanly between a healthy, cash-generative core (the parent plus clinics JECMI and hospital JMP) and a set of newer expansion vehicles that are the loss-making drag. (The revenue mix by service line is shown separately.)

The offering & ownership

The deal offers 15.00% of post-IPO capital, but the structure matters more than the headline. Only 10% is primary (new shares, cash to the company); the other 5% is a secondary divestment by selling shareholder DR. Dr. Waldensius Girsang, whose stake falls from 6.216% to 0.594% — a roughly 97% exit. One-third of the gross offering value therefore flows to a single exiting individual rather than into the business. Free float lands at 14.657% true public (15.00% including ESA), sitting at the regulatory floor, which the prospectus itself flags as a liquidity risk.

Ownership carries an unusual control/economic mismatch. The largest single holder is listed competitor PT Sarana Meditama Metropolitan Tbk (SAME / OMNI Hospitals) at 28% pre / 25.2% post — held since at least April 2022, so a long-standing strategic rather than a pre-IPO flip — yet SAME does not control. Control vests in PT Magna Selaras Lestari (MSL, ~9–10%), with Dr. Darwan Madja Purba as ultimate beneficial owner; Darwan's effective control of roughly 21% (his direct 11.79% plus MSL's 9.13%) still sits below SAME's 25.2%. Whether a shareholders' agreement or standstill explains this is an open question.

Lock-up is weaker than the structure implies. No POJK 25/2017 eight-month lock-up is triggered, because the prospectus asserts no party acquired shares below the offer price in the six months before registration. The only contractual restriction is MSL's controller undertaking to hold for 12 months — covering only ~9.1%. The remainder, roughly 76% of pre-IPO shares, is freely transferable from day one against a 14.7% float: SAME's 25.2%, Darwan's 11.8%, the two Istiantoro heirs' combined 17.8%, Waldensius's residual, and the fragmented doctor tail. The ESA covers 11,165,000 shares (2.29% of the offering, 0.343% post-IPO) for 111 employees, excluding directors and commissioners, priced at the offer price as a fixed allotment. It is effectively a company-funded grant — acquisition cost and final tax borne by the company — vesting over four years at a maximum 25%/year, KPI-gated (Good 60% / Outstanding 80% / Exceptional 100% of each annual tranche; Poor/Fair forfeit), with unvested shares forfeit on resignation. There is no MESOP/ESOP; note that one passage mislabels the scheme "Employee Stock Option" while every mechanic describes an allocation.

Governance & related parties

The board (Akta No.57, 9 Mar 2026) is chaired by the UBO himself, Dr. Darwan Madja Purba, as President Commissioner, alongside the founding Istiantoro family representative Agus Hermawan Istiantoro and an OMNI-aligned presence. Two of six commissioners are independent (33%), just above the 30% minimum — adequate but not a margin of safety. Independent Commissioner Heri Sunaryadi carries a capital-markets pedigree with a historical link to lead underwriter Trimegah, worth noting for independence perception though not a disqualifier. The two largest non-controlling individual holders, Rayyan and Nabbil Wardhana Istiantoro (8.897% each), inherited their stakes in 2024 from the late Dr. Vira Wardhana via will, hold no operating role, and carry no lock-up — a potential overhang. On related-party matters, the BCA and HSBC early repayments are stated to be non-affiliated transactions, while the NSB equity injection is an affiliated parent-to-subsidiary transaction handled under POJK 17/2020; the NSB land lessor is PT Hotel Indonesia Natour, a non-affiliated SOE. The legal record is clean: neither the company nor its directors and commissioners are party to any litigation — a genuine positive.

Reading the financials

The trailing numbers tell a deceleration-and-shock story. Revenue grew +13.2% (2023), +7.6% (2024), then just +4.4% (2025). More striking, net profit collapsed roughly 51% in 2024 — from Rp127,284m to Rp62,472m — as G&A leapt from Rp326bn to Rp425bn (+30%) against +7.6% revenue, driven by expansion start-up drag at the 2024 openings (RS JEC Orbita Makassar, KUM JEC Pasuruan, KUM JEC Kendari; +Rp31.5bn), a new sustainability-cost accounting policy (+Rp20.3bn), and higher borrowing cost (+Rp12.4bn). Operating margin was crushed from 21.7% to 12.8%. The 2025 recovery is real but partial: net profit of Rp73,760m attributable to parent remains about 35% below the 2023 peak of Rp114,075m. The recovery narrative is not yet in the trailing P&L.

Two balance-sheet mechanics interlock. First, the current ratio fell to 0.69x — confirmed by the liabilities note: at 31 Dec 2025 long-term bank debt is nil, because the entire Rp260,654m of BCA term debt (parent Rp49.2bn, Orbita Rp149.1bn, JCS Rp62.3bn) sits in current liabilities. Orbita and JCS breached covenants at year-end, making the facilities callable and forcing reclassification; the BCA waiver is dated 11 March 2026, after the balance-sheet date, so it cannot reverse the year-end classification. Orbita's breach is the more severe — DER 3.14x, ICR 0.90x (EBITDA does not cover interest), DSCR 0.44 — alongside JCS (DSCR 0.49, ICR 1.84). Second, equity is flat to declining (Rp830,634m → Rp811,734m → Rp810,995m) despite positive earnings, because of aggressive pre-IPO dividends: Rp55bn (2023), Rp70.2bn (2024), Rp48.1bn (2025), with the 2024 payout exceeding that year's net profit — a >100% cash payout. The deleveraging plan rests on the IPO proceeds repaying roughly Rp275bn of bank debt across the parent and the two breaching subsidiaries. Importantly, the headline reported DER (0.79x at 2025) overstates financial leverage by about 2x, because the prospectus's "DER" uses total liabilities, dominated by payables and lease/dividend obligations; interest-bearing financial leverage is a moderate ~0.33x (bank debt Rp267.4bn ÷ equity), or ~0.40x including PSAK-116 leases of Rp58.2bn. The HSBC recap loan (Rp192bn drawn ~April 2026) lifts gross financial debt to roughly Rp432bn by 30 June 2026 before the IPO pays it back down — leverage rising on the eve of listing to fund a dividend, then a genuine, sizeable de-lever.

Valuation

The ask is rich. On FY2025 attributable earnings against post-IPO shares (EPS Rp22.67), the trailing P/E is 52.9x at Rp1,200 and 61.8x at Rp1,400; even measured against the 2023 peak (EPS Rp35.06) it is 34.2x–39.9x, with P/B at roughly 3.3x–3.6x. That multiple capitalizes a recovery-and-expansion payoff the trailing P&L does not yet show, on decelerating revenue and a thin float. The sharpest valuation cross-check is internal to the cap table: SAME, the 25% non-controlling holder, is itself listed (OMNI Hospitals), so JEC's IPO multiple can be benchmarked directly against SAME's live trading multiple, plus MIKA, HEAL, and SILO. If OMNI/SAME trades materially cheaper than JEC's ask, that relative-value gap is the most honest read on the pricing. (Multiples are tabulated separately.)

Bottom line

JECX is a strong, accredited eye-care franchise with a healthy cash-generative core, a clean legal record, and a real demand tailwind — wrapped in an offering whose cash flows point largely backward rather than forward. The majority of company proceeds repays debt (up to 70.4% at the floor), Rp100bn of it backfilling a dividend-recap loan, while a third of the headline deal cashes out an exiting founder-doctor; profit sits 35% below its 2023 peak, two subsidiaries breached covenants, and only ~9% of shares are locked against a floor-level float priced at 53–62x trailing earnings. The deleveraging plan is credible and, if executed, resets the cost of capital — but the trailing numbers and the use of proceeds ask investors to pay a premium for a recovery they cannot yet see, and to fund an extraction that has largely already happened.